找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve

[復(fù)制鏈接]
查看: 28733|回復(fù): 46
樓主
發(fā)表于 2025-3-21 16:29:11 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Novel Therapeutics from Modern Biotechnology
副標(biāo)題From Laboratory to H
編輯Dale L. Oxender,Leonard E. Post (Vice President, D
視頻videohttp://file.papertrans.cn/669/668468/668468.mp4
概述Study Edition of the successful volume 137 in the Handbook of Experimental Pharmacology series * Original edition already sold out.Includes supplementary material:
叢書名稱Handbook of Experimental Pharmacology
圖書封面Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve
描述A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the "high-technology hype", although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech- nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, suc
出版日期Book 1999
關(guān)鍵詞Downstream Processing; Expression; Nucleotide; Tissue Engineering; Vivo; biotechnology; chemistry; chromato
版次1
doihttps://doi.org/10.1007/978-3-642-59990-3
isbn_softcover978-3-540-65927-3
isbn_ebook978-3-642-59990-3Series ISSN 0171-2004 Series E-ISSN 1865-0325
issn_series 0171-2004
copyrightSpringer-Verlag Berlin Heidelberg 1999
The information of publication is updating

書目名稱Novel Therapeutics from Modern Biotechnology影響因子(影響力)




書目名稱Novel Therapeutics from Modern Biotechnology影響因子(影響力)學(xué)科排名




書目名稱Novel Therapeutics from Modern Biotechnology網(wǎng)絡(luò)公開度




書目名稱Novel Therapeutics from Modern Biotechnology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Novel Therapeutics from Modern Biotechnology被引頻次




書目名稱Novel Therapeutics from Modern Biotechnology被引頻次學(xué)科排名




書目名稱Novel Therapeutics from Modern Biotechnology年度引用




書目名稱Novel Therapeutics from Modern Biotechnology年度引用學(xué)科排名




書目名稱Novel Therapeutics from Modern Biotechnology讀者反饋




書目名稱Novel Therapeutics from Modern Biotechnology讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:40:24 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:32:06 | 只看該作者
地板
發(fā)表于 2025-3-22 07:30:09 | 只看該作者
5#
發(fā)表于 2025-3-22 12:48:48 | 只看該作者
6#
發(fā)表于 2025-3-22 13:42:16 | 只看該作者
SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytiult in death. Infants with underlying cardiac or pulmonary disease, and some premature/low-birth-weight infants are at considerably higher risk of more severe disease and increased mortality from RSV infection, and are candidates for prophylactic intervention during the winter months. Although not w
7#
發(fā)表于 2025-3-22 19:33:57 | 只看該作者
Book 1999cal trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, suc
8#
發(fā)表于 2025-3-22 23:47:52 | 只看該作者
9#
發(fā)表于 2025-3-23 01:53:50 | 只看該作者
10#
發(fā)表于 2025-3-23 09:08:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 08:11
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
武夷山市| 汉寿县| 宁国市| 称多县| 山西省| 博兴县| 石林| 博兴县| 新绛县| 防城港市| 汉寿县| 若羌县| 江都市| 孝昌县| 枣阳市| 阳山县| 丰宁| 关岭| 武山县| 鱼台县| 兴国县| 浮山县| 巴马| 金阳县| 阜宁县| 开江县| 婺源县| 留坝县| 抚州市| 瑞丽市| 五大连池市| 武功县| 漳平市| 合水县| 新闻| 邳州市| 洪泽县| 北安市| 梅河口市| 樟树市| 南康市|